Explore

Trendline Trendline
CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026

CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026

CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026
Trendline Trendline
REGENXBIO Faces Setbacks with Duchenne Gene Therapy Amid Safety Concerns

REGENXBIO Faces Setbacks with Duchenne Gene Therapy Amid Safety Concerns

REGENXBIO Faces Setbacks with Duchenne Gene Therapy Amid Safety Concerns
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Trendline Trendline
BrainStorm Cell Therapeutics Announces Financial Results and Updates on ALS Treatment Development

BrainStorm Cell Therapeutics Announces Financial Results and Updates on ALS Treatment Development

BrainStorm Cell Therapeutics Announces Financial Results and Updates on ALS Treatment Development
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Trendline Trendline
Nanalysis Scientific Corp to Host First Quarter 2026 Conference Call for Investors

Nanalysis Scientific Corp to Host First Quarter 2026 Conference Call for Investors

Nanalysis Scientific Corp to Host First Quarter 2026 Conference Call for Investors
Trendline Trendline
FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress

Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Trendline Trendline
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026

Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026

Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026